...
首页> 外文期刊>Journal of Clinical Microbiology >Emergence and Rapid Spread of Carbapenem Resistance during a Large and Sustained Hospital Outbreak of MultiresistantAcinetobacter baumannii
【24h】

Emergence and Rapid Spread of Carbapenem Resistance during a Large and Sustained Hospital Outbreak of MultiresistantAcinetobacter baumannii

机译:发生多药耐药鲍曼不动杆菌大规模且持续的医院暴发期间,碳青霉烯耐药性的出现和快速传播

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Beginning in 1992, a sustained outbreak of multiresistantAcinetobacter baumannii infections was noted in our 1,000-bed hospital in Barcelona, Spain, resulting in considerable overuse of imipenem, to which the organisms were uniformly susceptible. In January 1997, carbapenem-resistant (CR)A. baumannii strains emerged and rapidly disseminated in the intensive care units (ICUs), prompting us to conduct a prospective investigation. It was an 18-month longitudinal intervention study aimed at the identification of the clinical and microbiological epidemiology of the outbreak and its response to a multicomponent infection control strategy. From January 1997 to June 1998, clinical samples from 153 (8%) of 1,836 consecutive ICU patients were found to contain CR A. baumannii. Isolates were verified to be A. baumannii by restriction analysis of the 16S-23S ribosomal genes and the intergenic spacer region. Molecular typing by repetitive extragenic palindromic sequence-based PCR and pulsed-field gel electrophoresis showed that the emergence of carbapenem resistance was not by the selection of resistant mutants but was by the introduction of two new epidemic clones that were different from those responsible for the endemic. Multivariate regression analysis selected those patients with previous carriage of CR A. baumannii(relative risk [RR], 35.3; 95% confidence interval [CI], 7.2 to 173.1), those patients who had previously received therapy with carbapenems (RR, 4.6; 95% CI, 1.3 to 15.6), or those who were admitted into a ward with a high density of patients infected with CR A. baumannii (RR, 1.7; 95% CI, 1.2 to 2.5) to be at a significantly greater risk for the development of clinical colonization or infection with CR A. baumannii strains. In accordance, a combined infection control strategy was designed and implemented, including the sequential closure of all ICUs for decontamination, strict compliance with cross-transmission prevention protocols, and a program that restricted the use of carbapenem. Subsequently, a sharp reduction in the incidence rates of infection or colonization with A. baumannii, whether resistant or susceptible to carbapenems, was shown, although an alarming dominance of the carbapenem-resistant clones was shown at the end of the study.
机译:从1992年开始,在我们位于西班牙巴塞罗那的1000张床位的医院中发现了多抗性鲍曼不动杆菌持续爆发,导致亚胺培南的过度使用,亚胺培南对这些细菌一律易感。 1997年1月,抗碳青霉烯(CR) A。鲍曼氏菌株在重症监护病房(ICU)中出现并迅速传播,促使我们进行前瞻性调查。这是一项为期18个月的纵向干预研究,旨在确定暴发的临床和微生物流行病学及其对多组分感染控制策略的反应。从1997年1月至1998年6月,在1836名连续ICU患者中,有153名(8%)的临床样本被发现含有CR A。鲍曼氏菌。分离株经验证为 A。通过对16S-23S核糖体基因和基因间隔区的限制性酶切分析。通过重复的基于外源回文序列的PCR和脉冲场凝胶电泳进行分子分型显示,碳青霉烯抗药性的产生不是通过选择抗性突变体,而是通过引入两个新的流行病克隆,它们与地方病不同。多元回归分析选择了先前携带CR A的患者。 baumannii (相对危险度[RR],35.3; 95%置信区间[CI],7.2至173.1),以前曾接受过碳青霉烯类药物治疗的患者(RR,4.6; 95%CI,1.3至15.6),或那些因CR A感染而被送往高密度病房的人。鲍曼氏菌(RR,1.7; 95%CI,1.2至2.5)在临床定植或感染CR A的风险显着更高。鲍曼氏菌菌株。因此,设计并实施了综合感染控制策略,包括顺序关闭所有用于消毒的ICU,严格遵守交叉传播预防方案,以及限制使用碳青霉烯的程序。随后, A感染或定植的发生率急剧下降。尽管在研究结束时显示出对碳青霉烯类耐药的克隆具有惊人的优势,但无论是否对碳青霉烯类耐药,都显示了鲍曼不动杆菌。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号